

Johannes G Ramaekers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9361421/publications.pdf>

Version: 2024-02-01

146
papers

6,846
citations

66343

42
h-index

74163

75
g-index

151
all docs

151
docs citations

151
times ranked

4973
citing authors

#	ARTICLE	IF	CITATIONS
1	Psychotomimetic symptoms after a moderate dose of a synthetic cannabinoid (JWH-018): implications for psychosis. <i>Psychopharmacology</i> , 2022, 239, 1251-1261.	3.1	12
2	The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. <i>Journal of Psychopharmacology</i> , 2022, 36, 309-320.	4.0	34
3	Prevalence of alcohol among drivers, riders and pedestrians injured in road traffic crashes in Cameroon: a cross-sectional study. <i>International Journal of Injury Control and Safety Promotion</i> , 2022, 29, 340-347.	2.0	1
4	Therapeutic effect of an ayahuasca analogue in clinically depressed patients: a longitudinal observational study. <i>Psychopharmacology</i> , 2022, 239, 1839-1852.	3.1	19
5	LSD and creativity: Increased novelty and symbolic thinking, decreased utility and convergent thinking. <i>Journal of Psychopharmacology</i> , 2022, 36, 348-359.	4.0	16
6	The clinical pharmacology and potential therapeutic applications of 5- <i>methoxy-N,N</i> -dimethyltryptamine (5-MeO-DMT). <i>Journal of Neurochemistry</i> , 2022, 162, 128-146.	3.9	31
7	Remembering Molly: Immediate and delayed false memory formation after acute MDMA exposure. <i>European Neuropsychopharmacology</i> , 2022, 57, 59-68.	0.7	3
8	Functional brain connectomes reflect acute and chronic cannabis use. <i>Scientific Reports</i> , 2022, 12, 2449.	3.3	9
9	Metabolomics and integrated network analysis reveal roles of endocannabinoids and large neutral amino acid balance in the ayahuasca experience. <i>Biomedicine and Pharmacotherapy</i> , 2022, 149, 112845.	5.6	6
10	Sex differences in acute cannabis effects revisited: Results from two randomized, controlled trials. <i>Addiction Biology</i> , 2022, 27, e13125.	2.6	18
11	Cannabis Use and Neuroadaptation: A Call for ¹⁸ F-Tetrahydrocannabinol Challenge Studies. <i>Frontiers in Psychiatry</i> , 2022, 13, 870750.	2.6	0
12	The use patterns of novel psychedelics: experiential fingerprints of substituted phenethylamines, tryptamines and lysergamides. <i>Psychopharmacology</i> , 2022, 239, 1783-1796.	3.1	7
13	Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses. <i>Neuroscience and Biobehavioral Reviews</i> , 2022, 138, 104689.	6.1	45
14	Effects of solriamfetol on on-the-road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea. <i>Human Psychopharmacology</i> , 2022, 37, .	1.5	8
15	Analgesic potential of macrodoses and microdoses of classical psychedelics in chronic pain sufferers: a population survey. <i>British Journal of Pain</i> , 2022, 16, 619-631.	1.5	4
16	Driving performance and neurocognitive skills of long-term users of sedating antidepressants. <i>Human Psychopharmacology</i> , 2021, 36, 1-12.	1.5	4
17	Use characteristics and harm potential of ecstasy in The Netherlands. <i>Drugs: Education, Prevention and Policy</i> , 2021, 28, 107-117.	1.3	3
18	Low Doses of LSD Acutely Increase BDNF Blood Plasma Levels in Healthy Volunteers. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 461-466.	4.9	71

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide Microdoses in Healthy Participants. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 658-666.	4.7	26
20	A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers. <i>Journal of Psychopharmacology</i> , 2021, 35, 398-405.	4.0	47
21	Reduced responsiveness of the reward system is associated with tolerance to cannabis impairment in chronic users. <i>Addiction Biology</i> , 2021, 26, e12870.	2.6	31
22	On-the-road driving performance of patients with central disorders of hypersomnolence. <i>Traffic Injury Prevention</i> , 2021, 22, 120-126.	1.4	2
23	An explorative approach to understanding individual differences in driving performance and neurocognition in long-term benzodiazepine users. <i>Human Psychopharmacology</i> , 2021, 36, e2778.	1.5	5
24	Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis. <i>Journal of Psychopharmacology</i> , 2021, 35, 537-546.	4.0	3
25	Naturalistic Use of Mescaline Is Associated with Self-Reported Psychiatric Improvements and Enduring Positive Life Changes. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 543-552.	4.9	58
26	Driving Impairment Following Vaporization of Cannabis—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1226.	7.4	1
27	Intoxication by a synthetic cannabinoid (JWH-018) causes cognitive and psychomotor impairment in recreational cannabis users. <i>Pharmacology Biochemistry and Behavior</i> , 2021, 202, 173118.	2.9	11
28	A placebo-controlled study of the effects of ayahuasca, set and setting on mental health of participants in ayahuasca group retreats. <i>Psychopharmacology</i> , 2021, 238, 1899-1910.	3.1	51
29	Spontaneous and deliberate creative cognition during and after psilocybin exposure. <i>Translational Psychiatry</i> , 2021, 11, 209.	4.8	46
30	Roadside surveys of drinking and driving in Cameroon. <i>Traffic Injury Prevention</i> , 2021, 22, 349-354.	1.4	4
31	Hazy memories in the courtroom: A review of alcohol and other drug effects on false memory and suggestibility. <i>Neuroscience and Biobehavioral Reviews</i> , 2021, 124, 291-307.	6.1	20
32	The why behind the high: determinants of neurocognition during acute cannabis exposure. <i>Nature Reviews Neuroscience</i> , 2021, 22, 439-454.	10.2	36
33	The Setting Questionnaire for the Ayahuasca Experience: Questionnaire Development and Internal Structure. <i>Frontiers in Psychology</i> , 2021, 12, 679016.	2.1	9
34	Reply to: Managing the high: developing legislation and detection methods for cannabis impairment. <i>Nature Reviews Neuroscience</i> , 2021, 22, 585-585.	10.2	0
35	Fatigue in Aviation: Safety Risks, Preventive Strategies and Pharmacological Interventions. <i>Frontiers in Physiology</i> , 2021, 12, 712628.	2.8	31
36	Persisting Effects of Ayahuasca on Empathy, Creative Thinking, Decentering, Personality, and Well-Being. <i>Frontiers in Pharmacology</i> , 2021, 12, 721537.	3.5	24

#	ARTICLE	IF	CITATIONS
37	Chiral Serum Pharmacokinetics of 4-Fluoroamphetamine after Controlled Oral Administration: Can (R)/(S)-Concentration Ratios Help in Interpreting Forensic Cases?. <i>Journal of Analytical Toxicology</i> , 2021, 45, 985-992.	2.8	7
38	A Phase 1, Dose-Ranging Study to Assess Safety and Psychoactive Effects of a Vaporized 5-Methoxy-N,N-Dimethyltryptamine Formulation (GH001) in Healthy Volunteers. <i>Frontiers in Pharmacology</i> , 2021, 12, 760671.	3.5	20
39	Intoxicated aggression: Do alcohol and stimulants cause dose-related aggression? A review. <i>European Neuropsychopharmacology</i> , 2020, 30, 114-147.	0.7	30
40	Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. <i>Progress in Neurobiology</i> , 2020, 185, 101732.	5.7	159
41	Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: effects on salivary IL-6, cortisol levels, affect, and non-judgment. <i>Psychopharmacology</i> , 2020, 237, 773-785.	3.1	61
42	Excretion of 4-fluoroamphetamine and three metabolites in urine after controlled oral ingestion. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 179, 113008.	2.8	6
43	Validating lane drifts as a predictive measure of drug or sleepiness induced driving impairment. <i>Psychopharmacology</i> , 2020, 237, 877-886.	3.1	11
44	Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study. <i>European Neuropsychopharmacology</i> , 2020, 41, 81-91.	0.7	62
45	Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. <i>Neuropsychopharmacology</i> , 2020, 45, 2003-2011.	5.4	127
46	Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study. <i>Journal of Psychopharmacology</i> , 2020, 34, 856-863.	4.0	14
47	Cannabis Crashes: Myths & Truths. <i>Drug and Alcohol Review</i> , 2020, 39, 287-288.	2.1	0
48	Acute Effects of 2C-E in Humans: An Observational Study. <i>Frontiers in Pharmacology</i> , 2020, 11, 233.	3.5	11
49	Cannabis increases susceptibility to false memory. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4585-4589.	7.1	21
50	Analysis of 4-fluoroamphetamine in cerumen after controlled oral application. <i>Drug Testing and Analysis</i> , 2020, 12, 968-974.	2.6	4
51	Blunted highs: Pharmacodynamic and behavioral models of cannabis tolerance. <i>European Neuropsychopharmacology</i> , 2020, 36, 191-205.	0.7	48
52	Semiquantitative Activity-Based Detection of JWH-018, a Synthetic Cannabinoid Receptor Agonist, in Oral Fluid after Vaping. <i>Analytical Chemistry</i> , 2020, 92, 6065-6071.	6.5	5
53	Effect of Cannabidiol and Δ^9 -Tetrahydrocannabinol on Driving Performance. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 2177.	7.4	106
54	False memory formation in cannabis users: a field study. <i>Psychopharmacology</i> , 2019, 236, 3439-3450.	3.1	10

#	ARTICLE	IF	CITATIONS
55	Cocaine enhances figural, but impairs verbal "flexible" divergent thinking. <i>European Neuropsychopharmacology</i> , 2019, 29, 813-824.	0.7	10
56	Detection of ⁹ THC in oral fluid following vaporized cannabis with varied cannabidiol (CBD) content: An evaluation of two point-of-collection testing devices. <i>Drug Testing and Analysis</i> , 2019, 11, 1486-1497.	2.6	32
57	On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. <i>Sleep</i> , 2019, 42, .	1.1	205
58	A First-in-Man Study with 4-Fluoroamphetamine Demonstrates it Produces a Mild Psychedelic State. <i>Journal of Psychoactive Drugs</i> , 2019, 51, 225-235.	1.7	5
59	Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. <i>Psychopharmacology</i> , 2019, 236, 2713-2724.	3.1	130
60	Neurocognition and Subjective Experience Following Acute Doses of the Synthetic Cannabinoid JWH-018: Responders Versus Nonresponders. <i>Cannabis and Cannabinoid Research</i> , 2019, 4, 51-61.	2.9	18
61	Pharmacokinetic properties of 4-fluoroamphetamine in serum and oral fluid after oral ingestion. <i>Drug Testing and Analysis</i> , 2019, 11, 1028-1034.	2.6	8
62	A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. <i>Psychopharmacology</i> , 2019, 236, 2653-2666.	3.1	99
63	Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis. <i>Psychopharmacology</i> , 2019, 236, 2677-2685.	3.1	26
64	Driving performance and neurocognitive skills of long-term users of benzodiazepine anxiolytics and hypnotics. <i>Human Psychopharmacology</i> , 2019, 34, e2715.	1.5	18
65	Pharmacokinetics of Single Doses of Methadone and Buprenorphine in Blood and Oral Fluid in Healthy Volunteers and Correlation With Effects on Psychomotor and Cognitive Functions. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 489-493.	1.4	2
66	Quantification of endogenous neurotransmitters and related compounds by liquid chromatography coupled to tandem mass spectrometry. <i>Talanta</i> , 2019, 192, 93-102.	5.5	51
67	Cannabis induced increase in striatal glutamate associated with loss of functional corticostriatal connectivity. <i>European Neuropsychopharmacology</i> , 2019, 29, 247-256.	0.7	45
68	Metabolomics predicts the pharmacological profile of new psychoactive substances. <i>Journal of Psychopharmacology</i> , 2019, 33, 347-354.	4.0	21
69	A clinical trial on the acute effects of methadone and buprenorphine on actual driving and cognitive function of healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 442-453.	2.4	22
70	Comparing the effects of oxazepam and diazepam in actual highway driving and neurocognitive test performance: a validation study. <i>Psychopharmacology</i> , 2018, 235, 1283-1294.	3.1	10
71	Orbital and Medial Prefrontal Cortex Functional Connectivity of Major Depression Vulnerability and Disease. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 348-357.	1.5	19
72	Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter. <i>Scientific Reports</i> , 2018, 8, 1061.	3.3	13

#	ARTICLE	IF	CITATIONS
73	Driving Under the Influence of Cannabis. JAMA - Journal of the American Medical Association, 2018, 319, 1433.	7.4	45
74	Driving under the influence of cocaine: Quantitative determination of basic drugs in oral fluid obtained during roadside controls and a controlled study with cocaine users. Drug Testing and Analysis, 2018, 10, 1285-1296.	2.6	10
75	MDMA-induced indifference to negative sounds is mediated by the 5-HT2A receptor. Psychopharmacology, 2018, 235, 481-490.	3.1	17
76	Pharmacokinetic properties of the synthetic cannabinoid JWH-018 in oral fluid after inhalation. Drug Testing and Analysis, 2018, 10, 644-650.	2.6	16
77	Excretion of metabolites of the synthetic cannabinoid JWH-018 in urine after controlled inhalation. Journal of Pharmaceutical and Biomedical Analysis, 2018, 150, 162-168.	2.8	8
78	Peripheral endocannabinoid concentrations are not associated with verbal memory impairment during MDMA intoxication. Psychopharmacology, 2018, 235, 709-717.	3.1	6
79	Neurocognition and subjective experience following acute doses of the synthetic cannabinoid JWH-018: a phase 1, placebo-controlled, pilot study. British Journal of Pharmacology, 2018, 175, 18-28.	5.4	34
80	Independent elevation of peripheral oxytocin concentrations and reduction in cognitive empathy during 4-fluoroamphetamine intoxication. Human Psychopharmacology, 2018, 33, e2680.	1.5	5
81	Drug liking and wanting, not impulsive action or reflection is increased by 4-fluoroamphetamine. Psychopharmacology, 2018, 235, 2349-2356.	3.1	8
82	A single dose of cocaine enhances prospective memory performance. Journal of Psychopharmacology, 2018, 32, 883-892.	4.0	4
83	Safety Profile and Neurocognitive Function Following Acute 4-Fluoroamphetamine (4-FA) Administration in Humans. Frontiers in Pharmacology, 2018, 9, 713.	3.5	14
84	Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution. Psychopharmacology, 2018, 235, 2979-2989.	3.1	134
85	The effects of the soluble guanylate cyclase stimulator riociguat on memory performance in healthy volunteers with a biperiden-induced memory impairment. Psychopharmacology, 2018, 235, 2407-2416.	3.1	10
86	Brain reactivity to alcohol and cannabis marketing during sobriety and intoxication. Addiction Biology, 2017, 22, 823-832.	2.6	22
87	Effect of chronic opioid therapy on actual driving performance in non-cancer pain patients. Psychopharmacology, 2017, 234, 989-999.	3.1	18
88	Human orbital and anterior medial prefrontal cortex: Intrinsic connectivity parcellation and functional organization. Brain Structure and Function, 2017, 222, 2941-2960.	2.3	28
89	Pharmacokinetic properties of the synthetic cannabinoid JWH-018 and of its metabolites in serum after inhalation. Journal of Pharmaceutical and Biomedical Analysis, 2017, 140, 215-222.	2.8	73
90	Multifaceted empathy of healthy volunteers after single doses of MDMA: A pooled sample of placebo-controlled studies. Journal of Psychopharmacology, 2017, 31, 589-598.	4.0	70

#	ARTICLE	IF	CITATIONS
91	Drugs and Driving Research in Medicinal Drug Development. Trends in Pharmacological Sciences, 2017, 38, 319-321.	8.7	36
92	A pooled analysis of on-the-road highway driving studies in actual traffic measuring standard deviation of lateral position (i.e., "weaving") while driving at a blood alcohol concentration of 0.5 g/L. Psychopharmacology, 2017, 234, 837-844.	3.1	41
93	Driving Performance of Depressed Patients who are Untreated or Receive Long-Term Antidepressant (SSRI/SNRI) Treatment. Pharmacopsychiatry, 2017, 50, 182-188.	3.3	24
94	Influence of Long-Term Benzodiazepine use on Neurocognitive Skills Related to Driving Performance in Patient Populations: A Review. Pharmacopsychiatry, 2017, 50, 189-196.	3.3	26
95	High reward expectancy during methylphenidate depresses the dopaminergic response to gain and loss. Social Cognitive and Affective Neuroscience, 2017, 12, 311-318.	3.0	17
96	Acute effects of cocaine and cannabis on response inhibition in humans: an ERP investigation. Addiction Biology, 2016, 21, 1186-1198.	2.6	18
97	Infusing pleasure: Mood effects of the consumption of a single cup of tea. Appetite, 2016, 103, 302-308.	3.7	9
98	Opposite effects of cannabis and cocaine on performance monitoring. European Neuropsychopharmacology, 2016, 26, 1127-1139.	0.7	15
99	On-the-road driving performance after use of the antihistamines mequitazine and l-mequitazine, alone and with alcohol. Psychopharmacology, 2016, 233, 3461-3469.	3.1	8
100	Neurocognitive performance following acute mephedrone administration, with and without alcohol. Journal of Psychopharmacology, 2016, 30, 1305-1312.	4.0	22
101	Subjective aggression during alcohol and cannabis intoxication before and after aggression exposure. Psychopharmacology, 2016, 233, 3331-3340.	3.1	37
102	Ayahuasca enhances creative divergent thinking while decreasing conventional convergent thinking. Psychopharmacology, 2016, 233, 3395-3403.	3.1	125
103	Cannabis and tolerance: acute drug impairment as a function of cannabis use history. Scientific Reports, 2016, 6, 26843.	3.3	50
104	Cannabis and cocaine decrease cognitive impulse control and functional corticostriatal connectivity in drug users with low activity DBH genotypes. Brain Imaging and Behavior, 2016, 10, 1254-1263.	2.1	52
105	Acute effects of cocaine and cannabis on reversal learning as a function of COMT and DRD2 genotype. Psychopharmacology, 2016, 233, 199-211.	3.1	20
106	Extended plasma cannabinoid excretion in chronic frequent cannabis smokers during sustained abstinence and correlation with psychomotor performance. Drug Testing and Analysis, 2016, 8, 682-689.	2.6	33
107	The sensitivity of laboratory tests assessing driving related skills to dose-related impairment of alcohol: A literature review. Accident Analysis and Prevention, 2016, 89, 31-48.	5.7	54
108	Bilastine: a new antihistamine with an optimal benefit-to-risk ratio for safety during driving. Expert Opinion on Drug Safety, 2016, 15, 89-98.	2.4	25

#	ARTICLE	IF	CITATIONS
109	Verbal Memory Impairment in Polydrug Ecstasy Users: A Clinical Perspective. PLoS ONE, 2016, 11, e0149438.	2.5	19
110	Smoked Cannabis' Psychomotor and Neurocognitive Effects in Occasional and Frequent Smokers. Journal of Analytical Toxicology, 2015, 39, 251-261.	2.8	106
111	MDMA, cannabis, and cocaine produce acute dissociative symptoms. Psychiatry Research, 2015, 228, 907-912.	3.3	28
112	Rivastigmine but not vardenafil reverses cannabis-induced impairment of verbal memory in healthy humans. Psychopharmacology, 2015, 232, 343-353.	3.1	26
113	Psychedelic symptoms of cannabis and cocaine use as a function of trait impulsivity. Journal of Psychopharmacology, 2015, 29, 324-334.	4.0	19
114	Emotion recognition during cocaine intoxication. European Neuropsychopharmacology, 2015, 25, 1914-1921.	0.7	15
115	Electroencephalography during on-the-road driving in older untreated insomnia patients and normal sleepers. Biological Psychology, 2015, 109, 20-28.	2.2	8
116	Evaluation of ⁹ â€”tetrahydrocannabinol detection using DrugWipe5S [®] screening and oral fluid quantification after Quantisalâ„¢ collection for roadside drug detection via a controlled study with chronic cannabis users. Drug Testing and Analysis, 2015, 7, 178-186.	2.6	26
117	Sensitivity and Validity of Psychometric Tests for Assessing Driving Impairment: Effects of Sleep Deprivation. PLoS ONE, 2015, 10, e0117045.	2.5	49
118	No Evidence that MDMA-Induced Enhancement of Emotional Empathy Is Related to Peripheral Oxytocin Levels or 5-HT1a Receptor Activation. PLoS ONE, 2014, 9, e100719.	2.5	72
119	On-the-road driving performance and driving-related skills in older untreated insomnia patients and chronic users of hypnotics. Psychopharmacology, 2014, 231, 2851-65.	3.1	22
120	Memory and mood during MDMA intoxication, with and without memantine pretreatment. Neuropharmacology, 2014, 87, 198-205.	4.1	28
121	Methylphenidate reduces functional connectivity of nucleus accumbens in brain reward circuit. Psychopharmacology, 2013, 229, 219-226.	3.1	46
122	Inhibition of ^{MDMA} â€”induced increase in cortisol does not prevent acute impairment of verbal memory. British Journal of Pharmacology, 2013, 168, 607-617.	5.4	20
123	Influence of Ethanol on the Pharmacokinetic Properties of ⁹ -Tetrahydrocannabinol in Oral Fluid. Journal of Analytical Toxicology, 2013, 37, 152-158.	2.8	17
124	Psychomotor Function in Chronic Daily Cannabis Smokers during Sustained Abstinence. PLoS ONE, 2013, 8, e53127.	2.5	69
125	A placebo-controlled study to assess Standardized Field Sobriety Tests performance during alcohol and cannabis intoxication in heavy cannabis users and accuracy of point of collection testing devices for detecting THC in oral fluid. Psychopharmacology, 2012, 223, 439-446.	3.1	52
126	Effects of stimulant drugs on actual and simulated driving: perspectives from four experimental studies conducted as part of the DRUID research consortium. Psychopharmacology, 2012, 222, 413-418.	3.1	15

#	ARTICLE	IF	CITATIONS
127	Medicinal Δ^9 -tetrahydrocannabinol (dronabinol) impairs on-road driving performance of occasional and heavy cannabis users but is not detected in standard field sobriety tests. <i>Addiction</i> , 2012, 107, 1837-1844.	3.3	91
128	Effects of Acute MDMA Intoxication on Mood and Impulsivity: Role of the 5-HT2 and 5-HT1 Receptors. <i>PLoS ONE</i> , 2012, 7, e40187.	2.5	77
129	Blockade of 5-HT2 Receptor Selectively Prevents MDMA-Induced Verbal Memory Impairment. <i>Neuropsychopharmacology</i> , 2011, 36, 1932-1939.	5.4	40
130	Tolerance and cross-tolerance to neurocognitive effects of THC and alcohol in heavy cannabis users. <i>Psychopharmacology</i> , 2011, 214, 391-401.	3.1	125
131	Residual effects of esmirtzapine on actual driving performance: overall findings and an exploratory analysis into the role of CYP2D6 phenotype. <i>Psychopharmacology</i> , 2011, 215, 321-332.	3.1	32
132	Pharmacokinetic Properties of Δ^9 -Tetrahydrocannabinol in Oral Fluid of Occasional and Chronic Users. <i>Journal of Analytical Toxicology</i> , 2010, 34, 216-221.	2.8	62
133	Involvement of Inferior Parietal Lobules in Prospective Memory Impairment during Acute MDMA (Ecstasy) Intoxication: An Event-Related fMRI Study. <i>Neuropsychopharmacology</i> , 2009, 34, 1641-1648.	5.4	39
134	Neurocognitive performance during acute THC intoxication in heavy and occasional cannabis users. <i>Journal of Psychopharmacology</i> , 2009, 23, 266-277.	4.0	294
135	An Experimental Study of Catechol-O-Methyltransferase Val158Met Moderation of Δ^9 -Tetrahydrocannabinol-Induced Effects on Psychosis and Cognition. <i>Neuropsychopharmacology</i> , 2006, 31, 2748-2757.	5.4	288
136	Cognition and motor control as a function of Δ^9 -THC concentration in serum and oral fluid: Limits of impairment. <i>Drug and Alcohol Dependence</i> , 2006, 85, 114-122.	3.2	262
137	Repeated-dose effects of mequitazine, cetirizine and dexchlorpheniramine on driving and psychomotor performance. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 79-86.	2.4	39
138	Stimulant effects of 3,4-methylenedioxymethamphetamine (MDMA) 75 μ g and methylphenidate 20 μ g on actual driving during intoxication and withdrawal. <i>Addiction</i> , 2006, 101, 1614-1621.	3.3	64
139	Acute Effects of 3,4-Methylenedioxymethamphetamine (MDMA) on Behavioral Measures of Impulsivity: Alone and in Combination with Alcohol. <i>Neuropsychopharmacology</i> , 2006, 31, 1048-1055.	5.4	95
140	Up in Smoke: Comparability of THC Dosing across Performance Studies. <i>Neuropsychopharmacology</i> , 2006, 31, 2800-2801.	5.4	7
141	High-Potency Marijuana Impairs Executive Function and Inhibitory Motor Control. <i>Neuropsychopharmacology</i> , 2006, 31, 2296-2303.	5.4	322
142	Dose related risk of motor vehicle crashes after cannabis use. <i>Drug and Alcohol Dependence</i> , 2004, 73, 109-119.	3.2	475
143	Dissociable Effects of a Single Dose of Ecstasy (MDMA) on Psychomotor Skills and Attentional Performance. <i>Journal of Psychopharmacology</i> , 2003, 17, 379-387.	4.0	76
144	Antidepressants and Driver Impairment. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 20-29.	2.2	211

#	ARTICLE	IF	CITATIONS
145	Antidepressants and driver impairment: empirical evidence from a standard on-the-road test. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 20-9.	2.2	85
146	Marijuana, alcohol and actual driving performance. <i>Human Psychopharmacology</i> , 2000, 15, 551-558.	1.5	248